|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Liver injury after aluminum potassium sulfate and tannic acid treatment of hemorrhoids显示文摘We are reporting a rare case of acute liver injury that developed after an internal hemorrhoid treatment with the aluminum potassium sulfate and tannic acid(ALTA) regimen. A 41-year-old man developed a fever and liver injury after undergoing internal hemorrhoid treatment with a submucosal injection of ALTA with lidocaine. The acute liver injury was classified clinically as hepatocellular and pathologically as cholestastic. We could not classify the mechanism of injury. High eosinophil and immunoglobulin E levels characterized the injury,and a drug lymphocyte stimulation test was negative on postoperative day 25. Fluid replacement for two weeks after hospitalization improved the liver injury. ALTA therapy involves injecting chemicals into the submucosa,from the rectum to the anus,and this is the first description of a case that developed a severe liver disorder after this treatment; hence,an analysis of future cases as they accumulate is desirable. | Kenichi Yoshikawa Reimi Kawashima Yuki Hirose Keiko Shibata Takafumi Akasu Noriko Hagiwara Takeharu Yokota Nami Imai Akira Iwaku Go Kobayashi Hirohiko Kobayashi Akiyoshi Kinoshita Nao Fushiya Hiroyuki Kijima Kazuhiko Koike Masayuki Saruta | 2017 | World Journal of Gastroenterology2017，23，27： | 5 |
| 2 | Clinical usefulness of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis显示文摘AIM To evaluate the therapeutic effects of ursodeoxycholic acid(UDCA) on autoimmune hepatitis(AIH).METHODS A total 136 patients who were diagnosed with AIH were included in our study. All of the patients underwent a liver biopsy, and had at least a probable diagnosis on the basis of either the revised scoring system or the simplified scores. Initial treatment included UDCA monotherapy(Group U, n = 48) and prednisolone(PSL) monotherapy(Group P, n = 88). Group U was further classified into two subgroups according to the effect of UDCA: Patients who had achieved remission induction with UDCA monotherapy and showed no sign of relapse(Subgroup U1, n = 34) and patients who additionally received PSL during follow-up(Subgroup U2, n = 14). We compared the clinical and histological findings between each groups, and investigated factorscontributing to the response to UDCA monotherapy.RESULTS In Group U, 34 patients(71%) achieved and maintained remission over 49(range: 8-90) mo(Subgroup U1) and 14 patients(29%) additionally received PSL(Subgroup U2) during follow-up. Two patients in Subgroup U2 achieved remission induction once but additionally required PSL administration because of relapse(15 and 35 mo after the start of treatment). The remaining 12 patients in Subgroup U2 failed to achieve remission induction during follow-up, and PSL was added during 7(range: 2-18) mo. Compared with Subgroup U2, Subgroup U1 had significantly lower alanine aminotransferase(ALT) levels at onset(124 IU/L vs 262 IU/L, P = 0.023) and a significantly higher proportion of patients with mild inflammation(A1) on histological examination(70.6% vs 35.7%, P = 0.025). When multivariate analysis was performed to identify factors contributing to the response to UDCA monotherapy, only a serum ALT level of 200 IU/L or lower was found to be associated with a significant difference(P = 0.013).CONCLUSION To prevent adverse events related to corticosteroids, UDCA monotherapy for AIH needs to be considered in patients with a serum ALT level of 200 IU/L or lower. | Yuichi Torisu Masanori Nakano Keiko Takano Ryo Nakagawa Chisato Saeki Atsushi Hokari Tomohisa Ishikawa Masayuki Saruta Mikio Zeniya | 2017 | World Journal of Hepatology2017，9，1： | 3 |
| 3 | Effects of denosumab treatment in chronic liver disease patients with osteoporosis显示文摘BACKGROUND Effective treatment of osteoporosis is essential for improving morbidity and health-related quality of life in chronic liver disease(CLD)patients.Denosumab has been shown to increase bone mineral density(BMD)and decrease the risk of osteoporotic fracture in the general population.However,there are few reports evaluating the efficacy of denosumab in CLD patients.AIM To investigated the effects and safety of denosumab in CLD patients with osteoporosis.METHODS Sixty CLD patients with osteoporosis were subcutaneously administered denosumab once every 6 mo.The study period for evaluating efficacy and safety was 12 mo.Changes from baseline in BMD at the lumbar spine,femoral neck,and total hip were evaluated at 12 mo of denosumab treatment.Bone turnover and quality were assessed by measuring serum tartrate-resistant acid phosphatase-5b(bone resorption marker),serum total procollagen type I N-terminal propeptide(bone formation maker),and plasma pentosidine(bone quality marker).RESULTS Among the 405 CLD patients,138(34.1%)patients were diagnosed with osteoporosis;among these,78 patients met the exclusion criteria and thus 60 patients were finally included in the present study.The median percentage changes from baseline to 12 mo of denosumab treatment in BMD at the lumbar spine,femoral neck,and total hip were+4.44%,+3.71%,and+4.03%,respectively.Denosumab significantly improved BMD,regardless of sex,patient age,and presence of liver cirrhosis.Serum tartrate-resistant acid phosphatase-5b and procollagen type I N-terminal propeptide levels constantly and significantly declined after denosumab treatment(P<0.001).Plasma pentosidine levels were also significantly lower at 12 mo of treatment(P=0.010).No patients experienced fractures and moderate-to-severe adverse events,except for transient hypocalcemia.CONCLUSION Denosumab treatment was safe and increased BMD,suppressed bone turnover,and improved bone quality marker levels in CLD patients with osteoporosis,irrespective of differences in baseline characteristics. | Chisato Saeki Mitsuru Saito Tsunekazu Oikawa Masanori Nakano Yuichi Torisu Masayuki Saruta Akihito Tsubota | 2020 | World Journal of Gastroenterology2020，26，33： | 3 |
| 4 | Endoscopic submucosal dissection in a patient with esophageal adenoid cystic carcinoma显示文摘We report the first use of endoscopic submucosal dissection(ESD) for the treatment of a patient with adenoid cystic carcinoma of the esophagus(EACC). An 82-year-old woman visited our hospital for evaluation of an esophageal submucosal tumor. Endoscopic examination showed a submucosal tumor in the middle third of the esophagus. The lesion partially stained with Lugol's solution,and narrow band imaging with magnification showed intrapapillary capillary loops with mild dilatation and a divergence of caliber in the center of the lesion. Endoscopic ultrasound imaging revealed a solid 8 mm × 4.2 mm tumor,primarily involving the second and third layers of the esophagus. A preoperative biopsy was non-diagnostic. ESD was performed to resect the lesion,an 8 mm submucosal tumor. Immunohistologically,tumor cells differentiating into ductal epithelium and myoepithelium were observed,and the tissue type was adenoid cystic carcinoma. There was no evidence of esophageal wall,vertical stump or horizontal margin invasion with p T1 b-SM2 staining(1800 μm from the muscularis mucosa). Further studies are needed to assess the use of ESD for the treatment of patients with EACC. | Kenichi Yoshikawa Akiyoshi Kinoshita Yuki Hirose Keiko Shibata Takafumi Akasu Noriko Hagiwara Takeharu Yokota Nami Imai Akira Iwaku Go Kobayashi Hirohiko Kobayashi Nao Fushiya Hiroyuki Kijima Kazuhiko Koike Haruka Kaneyama Keiichi Ikeda Masayuki Saruta | 2017 | World Journal of Gastroenterology2017，23，45： | 3 |
| 5 | Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma显示文摘As the incidence of hepatocellular carcinoma(HCC) caused by infection with the hepatotropic viruses hepatitis B and hepatitis C decreases, greater attention has become focused on HCC caused by nonalcoholic steatohepatitis(NASH), an advanced form of nonalcoholic fatty liver disease which has shown increasing prevalence in correspondence with the overall increase in metabolic syndrome over the recent decades. Several clinical population studies have shown a positive relationship between NASH and HCC, while also providing initial insights into the underlying mechanisms of HCC development from NASH. Research into the pathological progression of NASH to HCC has advanced by use of several beneficial rodent models. In this review, we summarize the established mouse models for preclinical research of NASH-associated HCC and discuss the underlying hepatic mechanisms of NASH-related tumorigenesis identified to date that could lead to new targets for treatment and prevention. | Kazuki Takakura Tsunekazu Oikawa Yoichi Tomita Yusuke Mizuno Masanori Nakano Chisato Saeki Yuichi Torisu Masayuki Saruta | 2018 | World Journal of Gastroenterology2018，24，18： | 2 |
| 6 | Development of an anisotropic conductive adhesive film(ACAF) from epoxy resins 显示文摘 | Asai Ueki Saruta | 1995 | J Appl Sci1995，56，： | 2 |
| 7 | Cloning and characterization of a novel gene promoting uretefic bud branching in the metanephros 显示文摘 | Araki T Hayashi M Saruta T | 2003 | Kidney Int2003，16，： | 1 |
| 8 | Status of home blood pressure measured in morning and evening:Evaluation in normotensives and hypertensives in Japanese urban population显示文摘 | Kawabe H Saito I Saruta T | 2005 | Hypertens Res2005，28，6： | 1 |
| 9 | ALDosterone breakthrough during angiotensin-converting enzyme inhibitor therapy显示文摘 | Sato A Saruta T | 2003 | Am J Hypertens2003，16，： | 1 |
| 10 | Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension显示文摘 | Saruta T Ogihara T Matsuoka H | 2007 | Hypertens Res2007，30，8： | 1 |
| 11 | Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension:a randomized,doubleblind,placebo-controlled,doseranging study显示文摘 | Saruta T Kageyama S Ogihara T | 2004 | J Clin Hypertens(Greenwich)2004，6，4： | 1 |
| 12 | Capsule endoscopy in the evaluation and management of inflammatory bowel disease:a future pers-pective显示文摘 | Saruta M Papadakis KA | 2009 | Expen Rve Mol Diagu2009，9，1： | 1 |
| 13 | Target blood pressure for treatment of isolated systolic hypertension in the elderly:valsartan in elderly isolated systolic hypertension study显示文摘 | Ogihara T Saruta T Rakugi H | | 0，，02： | 1 |
| 14 | Aldosterone breakthrough during angiotensin- converting enzyme inhibitor therapy 显示文摘 | Sato A and Saruta T | 2003 | Am J Hypertens2003，16，9： | 1 |
| 15 | ALDosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy显示文摘 | Sato A Saruta T | 2001 | J Int Med Res2001，29，： | 1 |
| 16 | Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy 显示文摘 | Sato A and Saruta T | 2001 | J Int Med Res2001，29，1： | 1 |
| 17 | Anti - proteinuric effects ofmineralortiaoid receptor blockade inpatients with chronic re-nal disease显示文摘 | Sato A Hayash K Saruta T | 2005 | Am Hypertens2005，18，1： | 1 |
| 18 | Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy:a 3-year follow-up显示文摘 | Okada H Saruta T | 2000 | Clin Nephrol2000，54，5： | 1 |
| 19 | Involvement of aldosterone in left ventrieular hypertrophy of patients with end-stage renal failure treated with hemodialysis显示文摘 | SATO A FUNDER JW SARUTA T | 1999 | Am J Hypertens1999，12，91： | 1 |
| 20 | Expression and functional characterization of Foxp3^+ CD4^+ regulatory T cells in ulcerative colitis 显示文摘 | Yu Q T Saruta M Avanesyan A | 2007 | Inflamm Bowel Dis2007，13，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员